Neimeth International Pharmaceuticals Plc

NGSE:NEIMETH Stock Report

Market Cap: ₦11.3b

Neimeth International Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Neimeth International Pharmaceuticals's earnings have been declining at an average annual rate of -75.2%, while the Pharmaceuticals industry saw earnings growing at 16.2% annually. Revenues have been growing at an average rate of 2.4% per year.

Key information

-75.2%

Earnings growth rate

-71.8%

EPS growth rate

Pharmaceuticals Industry Growth21.6%
Revenue growth rate2.4%
Return on equityn/a
Net Margin-38.0%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Neimeth International Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NGSE:NEIMETH Revenue, expenses and earnings (NGN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 244,469-1,6991,1150
30 Sep 243,793-1,9831,4440
30 Jun 242,909-2,2151,4160
31 Mar 242,389-2,5981,7080
31 Dec 232,210-2,8651,6360
30 Sep 231,919-1,0971,3890
30 Jun 232,242-9531,4100
31 Mar 232,462-3831,0060
31 Dec 222,919-3251,2040
30 Sep 222,703-1101,1250
30 Jun 222,882521,1740
31 Mar 222,750331,1780
31 Dec 212,8441401,1330
30 Sep 213,0472711,0740
30 Jun 212,824601,0050
31 Mar 212,9561841,0010
31 Dec 202,627-499840
30 Sep 202,8392129390
30 Jun 202,9674278930
31 Mar 202,5602717800
31 Dec 192,7514427710
30 Sep 192,3712207450
30 Jun 192,3451188030
31 Mar 192,3681248990
31 Dec 182,102-59030
30 Sep 182,2691488970
30 Jun 181,952-918560
31 Mar 181,810-1878720
31 Dec 171,791-1508710
30 Sep 171,534-4119580
30 Jun 171,718-3119700
31 Mar 171,816-2319580
31 Dec 161,743-2359130
30 Sep 162,002658390
30 Jun 161,664-1628970
31 Mar 161,808-549280
31 Dec 151,588-2169230
30 Sep 151,461-3368890
30 Jun 151,313-2978760
31 Mar 151,261-3978560
31 Dec 141,429-3729070
30 Sep 141,628-2298910
30 Jun 142,0001161,4620
31 Mar 142,105869040

Quality Earnings: NEIMETH is currently unprofitable.

Growing Profit Margin: NEIMETH is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NEIMETH is unprofitable, and losses have increased over the past 5 years at a rate of 75.2% per year.

Accelerating Growth: Unable to compare NEIMETH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEIMETH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.7%).

Return on Equity

High ROE: NEIMETH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 00:56
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neimeth International Pharmaceuticals Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullMeristem Securities Limited